Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for many malignant and non-malignant diseases. As survival improves, the frequency of late effects, among which chronic GVHD (cGVHD) is the most significant, also increases. 1 cGVHD may affect any organ in the body, with a behaviour resembling an autoimmune disease, including serositis (pleural/ pericardial effusion and ascites).
Standard treatment of pericardial effusion (surgery and antiinflamatories) offers poor results when recurrences happen. Recently, a favourable experience using infliximab for recurrent pericardial effusion has been reported. 2 We present a case of pericardial effusion attributed to cGVHD, which responded successfully to immunosuppressive treatment with infliximab.
Our patient is a boy born in October 2000, and diagnosed in December 2008 with acute T-lymphoblastic leukaemia, without cytogenetic alterations. Treatment was established according to the Very High Risk group of the protocol of the Sociedad Españ ola de Hematología Pediátrica (SHOP-LAL-2005), due to leukocytosis over 200.000 per mm 3 at diagnosis. CR, as evaluated by flow cytometry of BM aspirate, was achieved on day 14 of therapy and persisted throughout all the treatment. Chemotherapy continued for 7 months. The patient had an HLA-identical sibling, so following the end of chemotherapy, a familial BMT was performed in July 2009.
Conditioning regimen was TBI (1200 cGy) and CY (120 mg/kg). Starting on day À 1, CYA was administered as GVHD prophylaxis. On day þ 28, metilprednisolone was initiated due to cutaneous acute GVHD (aGVHD). The patient was discharged from hospital on day þ 31, with CYA and steroid treatment. Resolution of skin lesions allowed tapering of steroids from day þ 35.
In the following months, the patient required hospital admission twice (days þ 86 and þ 131) because of abdominal pain and diarrhoea suggestive of intestinal GVHD. Although colonoscopies were negative, steroid treatment was restarted and maintained until day þ 126. Micophenolate mofetil (MM) was added to the treatment in the second episode.
On day þ 188, a routine 2D echocardiogram showed mild pericardial effusion. At the time, GVHD treatment included CYA and MM, and no changes were made. A week later (day þ 194) the effusion had increased significantly (Figure 1) . The patient underwent a pericardiocentesis, evacuating approximately 250 ml of pericardial fluid. Microbiological studies (PCR for detection of CMV, herpes simplex I and II, human herpes 6, Epstein-Barr and varicella-zoster; bacterial, mycobacterial and fungal microscopy and culture) were negative. Anti-inflamatory treatment with ibuprofen was started, with favourable response. The pericardial drainage tube was withdrawn after 5 days, and the patient was discharged from hospital on day þ 200.
Control 2D echo on day þ 210 showed again an important increase of the pericardial effusion, requiring pericardiotomy. Again, approximately 250 ml of microbiologically negative pericardial fluid were obtained. On the following days, the drainage debit was high and constant, despite the addition of indometacin to the treatment.
On day þ 232, with a strong suspicion of an immune (GVHD) cause to the effusion, and after 3 weeks of unsuccessful antiinflammatory treatment, immunosupresory treatment was started with IV infliximab at 10 mg/kg once weekly. On day þ 244, 2 days after the second infusion of infliximab, the drainage tube could be withdrawn and the patient was discharged from hospital. Two more infusions were administered as outpatient treatment.
There were no significant side effects from the administration of infliximab.
Further follow-up has been satisfactory, with neither new cardiologic symptoms nor serositis. Immunosuppression withdrawal started at þ 1 year post HSCT and although it was carried out slowly, it was completed without complications on month þ 19 post HSCT. Last evaluation was þ 29 months post HSCT and showed CR in BM, with a full donor chimerism in peripheral blood, a fully reconstituted immune system, and no signs of GVHD.
cGVHD is the most significant nonrelapse cause of morbidity and mortality following allo-HSCT for malignant diseases. Incidence in long-term survivors is roughly 60% in adult population, and 25-40% in children. It is likely to rise due to the increasing use of alternative donors and peripheral blood as source for stem cells. 3 Acute GVHD is a well-defined disease, which affects skin, liver and/or gastrointestinal tract. cGVHD symptoms are much more diverse, making diagnosis and treatment a challenge.
Classical criteria for cGVHD established by the Seattle group defined day þ 100 as the frontier between acute and chronic disease, and classified cGVHD in localised or extensive. 4 In 2005, a consensus conference of the National Institutes of Health proposed a new classification based on symptoms regardless of time of onset. Among these symptoms, serositis is considered as a plausible, although non-typical, manifestation of cGVHD. 
